Interpace Biosciences, Inc. filed Pre-Effective Amendment No. 2 to its Form S-1 registration statement with the SEC on October 30, 2026, covering a proposed firm commitment underwritten offering of 3,100,000 shares of common stock at an estimated price range of $6.00 to $7.00 per share.

Key Highlights

  • Offering size: 3,100,000 shares of common stock, $0.01 par value per share, in a firm commitment underwritten offering.
  • Price range: The company estimates a public offering price between $6.00 and $7.00 per share, with a midpoint of $6.50 used throughout the prospectus.
  • Last reported price: Common stock closed at $5.72 per share on the OTCID on October 29, 2026.
  • Over-allotment option: Underwriters hold an option to purchase up to an additional 465,000 shares within 30 days of the prospectus date.
  • Nasdaq application: The company has applied to list its common stock on the Nasdaq Capital Market under the symbol "IDXG"; closing is contingent on receiving conditional Nasdaq approval.
  • Reverse stock split: The Board approved a one-for-five reverse stock split, effected at 12:01 a.m. Eastern Time on August 27, 2026; all share and per-share figures in the prospectus reflect this split.
  • Company classification: Interpace Biosciences is classified as a non-accelerated filer and a smaller reporting company under federal securities laws.

Interpace Biosciences Seeks Nasdaq Listing Through Amended Registration

According to the filing, Interpace Biosciences, Inc., a Delaware corporation headquartered at Waterview Plaza, Suite 310, 2001 Route 46, Parsippany, NJ 07054, is pursuing a capital raise through a firm commitment underwritten public offering. The company's common stock is currently quoted on the OTCID tier operated by OTC Markets Group Inc. under the symbol "IDXG," and the filing notes that the company has applied to transfer its listing to the Nasdaq Capital Market under the same symbol. The prospectus states that "the closing of this offering is contingent upon receiving conditional approval from Nasdaq of such listing" and adds that "no assurance can be given that our listing application will be approved."

The filing discloses that the Board of Directors approved a one-for-five reverse stock split of the company's outstanding common stock on August 20, 2026, which was effected as of 12:01 a.m. Eastern Time on August 27, 2026. All share and per-share numbers in the prospectus reflect this reverse split, though documents incorporated by reference that were filed before August 27, 2026 do not, unless otherwise stated. The company operates under Standard Industrial Classification Code 3841, indicating a medical instruments and apparatus segment focus. Thomas W. Burnell, President, Chief Executive Officer, and Chairman of the Board, is identified as the agent for service of process. The underwriters for the offering are Lake Street and Laidlaw and Company (UK) Ltd.

The filing carries Registration No. 333-299123 and notes that the offering price per share will be determined between the representative of the underwriters and the company at the time of pricing. The prospectus states that the public offering price "may be at a discount to the current market price" and that "the recent market price and the midpoint of the price range set forth above of $6.50 per share used throughout this prospectus may not be indicative of the final public offering price." The company describes investment in its securities as involving "a high degree of risk" and directs prospective investors to the Risk Factors section beginning on page 13 of the prospectus.

What Was Disclosed

Interpace Biosciences filed Pre-Effective Amendment No. 2 to its S-1 on October 30, 2026, proposing to sell 3,100,000 shares at $6.00 to $7.00 per share in a firm commitment offering, with a conditional Nasdaq listing application pending and an over-allotment option for 465,000 additional shares.